About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Amgen Inc. v. Amneal Pharmaceuticals LLC (Fed. Cir. 2020) | Main | Webinar on PTAB Developments »

January 09, 2020

Comments

A comparable bill in 2018 was H.R. 5026, Advancing Access to Personalized Medicine. The language in this Senate proposal has been altered in a small but very significant way. In 2018, H.R. 5026 provided whole genome sequencing (WGS) for Medicaid babies or children IN an intensive care unit "AND" was a specialist certifying they had a likely unknown genetic disease. This is reasonable; see Farnaes, WGS decreases infant morbidity in ICU's, 2018, NPJ Genomic Medicine 3:10.

A small change in the new language provides WGS testing for children in an ICU, "OR," with a likely genetic disease. The second clause in the new bill points to a broad range of children; it would include many children who need targeted, not WGS testing. There are also still gaps and undefined areas in whole exome/whole genome sequencing relative to targeted sequencing (e.g. Gotway, Clin Chem 66:199,2020).

Thanks Bruce for the insight. Do you think the mare targeted genetic analysis will be available for reimbursement using selective assessment of the data?

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name is required. Email address will not be displayed with the comment.)

April 2020

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30